載入...
Leveraging National Cancer Institute Programmatic Collaboration for Single Radiopharmaceutical Drug Master Files
Targeted radiopharmaceutical conjugates intended for therapeutic use often are made of three key components, a decaying radionuclide, a chemical chelator/linker, and a targeted molecular entity. The National Cancer Institute (NCI) Experimental Therapeutics Program has accepted four radiopharmaceutic...
Na minha lista:
| 發表在: | Front Oncol |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Frontiers Media S.A.
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6611355/ https://ncbi.nlm.nih.gov/pubmed/31316916 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00573 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|